180 related articles for article (PubMed ID: 17013853)
1. Development of sarcoidosis during etanercept therapy.
González-López MA; Blanco R; González-Vela MC; Fernández-Llaca H; Rodríguez-Valverde V
Arthritis Rheum; 2006 Oct; 55(5):817-20. PubMed ID: 17013853
[No Abstract] [Full Text] [Related]
2. Australian data do not support current Pharmaceutical Benefits Scheme criteria for use of tumour necrosis factor-alpha inhibitors in ankylosing spondylitis.
Schachna L; Brown MA
Intern Med J; 2006 Nov; 36(11):755-6. PubMed ID: 17040370
[No Abstract] [Full Text] [Related]
3. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
Pfueller CF; Seipelt E; Zipp F; Paul F
Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
[No Abstract] [Full Text] [Related]
4. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis?
Barthel HR
Arthritis Rheum; 2001 Aug; 45(4):404. PubMed ID: 11501730
[No Abstract] [Full Text] [Related]
5. New-onset psoriasis associated with etanercept therapy.
Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
[No Abstract] [Full Text] [Related]
6. Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept.
Takatori S; Kamata Y; Murosaki T; Iwamoto M; Minota S
J Rheumatol; 2010 Jan; 37(1):210-1. PubMed ID: 20040649
[No Abstract] [Full Text] [Related]
7. Acute myelogenous leukaemia following etanercept therapy.
Bakland G; Nossent H
Rheumatology (Oxford); 2003 Jul; 42(7):900-1. PubMed ID: 12826706
[No Abstract] [Full Text] [Related]
8. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
[No Abstract] [Full Text] [Related]
9. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
Braun J; van der Horst-Bruinsma IE; Huang F; Burgos-Vargas R; Vlahos B; Koenig AS; Freundlich B
Arthritis Rheum; 2011 Jun; 63(6):1543-51. PubMed ID: 21630245
[TBL] [Abstract][Full Text] [Related]
10. Effect of etanercept on iritis in patients with ankylosing spondylitis.
Rosenbaum JT
Arthritis Rheum; 2004 Nov; 50(11):3736-7. PubMed ID: 15529379
[No Abstract] [Full Text] [Related]
11. Survival and safety of treatment with infliximab in the elderly population.
Chevillotte-Maillard H; Ornetti P; Mistrih R; Sidot C; Dupuis J; Dellas JA; Tavernier C; Maillefert JF
Rheumatology (Oxford); 2005 May; 44(5):695-6. PubMed ID: 15705631
[No Abstract] [Full Text] [Related]
12. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
[No Abstract] [Full Text] [Related]
13. Granulomatous disease in a child treated with etanercept.
Alhajri M; Aljumaah S; Aleyouni Y; Al-Qahtani F; Alhazzaa S; Al-Mayouf SM
Int J Rheum Dis; 2013 Aug; 16(4):472-4. PubMed ID: 23826822
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
[TBL] [Abstract][Full Text] [Related]
15. Development of sarcoidosis following etanercept treatment: a report of three cases.
Skoie IM; Wildhagen K; Omdal R
Rheumatol Int; 2012 Apr; 32(4):1049-53. PubMed ID: 20062997
[TBL] [Abstract][Full Text] [Related]
16. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
17. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
Woo JH; Lee HJ; Sung IH; Kim TH
J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
[TBL] [Abstract][Full Text] [Related]
18. Results from an open-label extension study of etanercept in ankylosing spondylitis.
Davis J; Webb A; Lund S; Sack K
Arthritis Rheum; 2004 Apr; 51(2):302-4. PubMed ID: 15077279
[No Abstract] [Full Text] [Related]
19. Relapse of sarcoidosis upon treatment with etanercept.
Louie GH; Chitkara P; Ward MM
Ann Rheum Dis; 2008 Jun; 67(6):896-8. PubMed ID: 18474661
[No Abstract] [Full Text] [Related]
20. Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?
Wendling D; Toussirot E
J Rheumatol; 2007 Aug; 34(8):1647-9. PubMed ID: 17696283
[No Abstract] [Full Text] [Related]
[Next] [New Search]
